Tamoxifen in breast cancer: Not so easy to write off

Breast

Volumn 17, Issue 2, 2008, Pages 121-124

  Munshi, Anusheel ^a   Singh, Preetanjali ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Breast cancer; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CHOLESTEROL; CYTOCHROME P450 2D6; EXEMESTANE; GONADORELIN DERIVATIVE; INOSITOL; LETROZOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TAMOXIFEN;

ARTICLE; BONE DENSITY; BONE TURNOVER; BREAST CANCER; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER RECURRENCE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG COST; DRUG WITHDRAWAL; DYSPAREUNIA; ENDOMETRIOSIS; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; EYE DISEASE; FRACTURE; GENETIC ANALYSIS; HOT FLUSH; HUMAN; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MONOTHERAPY; OSTEOLYSIS; OVARIECTOMY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEXUAL DYSFUNCTION; SIDE EFFECT; THROMBOEMBOLISM; UTERUS CANCER; UTERUS DISEASE; UTERUS MYOMA; VAGINAL DRYNESS; VASOMOTOR DISORDER;

EID: 41549097291     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2007.08.010     Document Type: Article

References (28)

1. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2 (1896) 104-107
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365 (2005) 1687-1717
3. Nayfield S.G., and Gorin M.B. Tamoxifen-associated eye disease. A review. J Clin Oncol 14 (1996) 1018-1026
4. Cosman F., Baz-Hecht M., Cushman M., Vardy M.D., Cruz J.D., and Nieves J.W. Short-term effects of estrogen, tamoxifen and raloxifen on hemostasis: a randomized-controlled study and review of the literature. Thromb Res 116 (2005) 1-13
5. Gianni L., Panzini I., Li S., Gelber R.D., Collins J., Holmberg S.B., et al. Ocular toxicity during adjuvant chemo endocrine therapy for early breast cancer; results from I International Breast Cancer Study Group trials. Cancer 106 (2006) 505-513
6. Liu C.L., Huang J.K., Cheng S.P., Chang Y.C., Lee J.J., and Liu T.P. Fatty liver and transaminase changes with adjuvant tamoxifen therapy. Anticancer Drugs 17 (2006) 709-713
7. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7:633-43.
8. Carlson R.W., Hudis C.A., and Pritchard K.I. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw 4 (2006) 971-979
9. Smith M.L., Somlo G., Theriault R., War J.H., Winer E.P., and Wolff A.C. For the national comprehensive cancer network. The national comprehensive cancer network practice guidelines for breast cancer. Oncology (Basel) 14 (2000) 33-49
10. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S., Thurlimann B., and Senn H.J. Panel members meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16 (2005) 1569-1583
11. Ken G. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst 97 (2005) 412-413
12. Punglia RS, Winer EP, Weeks JC, Burstein HJ. Could treatment with tamoxifen be superior to aromatase inhibitors in early-stage breast cancer after pharmacogenomic testing? A modeling analysis. J Clin Oncol 2007. In: ASCO annual meeting proceedings. Part I, vol. 25, no. 18S (June 20 Supplement), 2007. p. 502.
13. Ernst T., Chang L., Cooray D., Salvador C., Jovicich J., Walot I., et al. The effects of tamoxifen and estrogen on brain metabolism in elderly women. J Natl Cancer Inst 94 (2002) 241-248
14. BC Cancer Agency Breast Tumour Group. (BRAJTAM) BCCA protocol summary for adjuvant therapy for breast cancer using tamoxifen. Vancouver: BC Cancer Agency; 1 July 2005.
15. Assikis V.J., and Jordan V.C. Risk and benefits of tamoxifen therapy. Oncology 11 (1997) 21-23
16. McEvoy GK, editor. AHFS 2006 drug information. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2006. p. 1185-92.
17. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 (1998) 1371-1388
18. Reis S.E., Costantino J.P., Wickerham D.L., et al. Cardiovascular effects of tamoxifen in women with and without heart disease: breast cancer prevention trial. J Natl Cancer Inst 93 (2001) 16-21
19. Jakesz R., Jonat W., Gnant M., Mittlboeck M., Greil R., Tausch C., et al. ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
20. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., et al., Goldhirsch Breast International Group (BIG) 1-98 Collaborative Group, A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353 (2005) 2747-2757
21. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97 (2005) 1262-1271
22. Coleman R.E., Banks L.M., Girgis S.I., Kilburn L.S., Vrdoljak E., Fox J., et al. Intergroup Exemestane Study group. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 8 (2007) 119-127
23. Smith I.E., Dowsett M., Yap Y.S., Walsh G., Lønning P E., Santen R.J., et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 1 (2006) 2444-2447
24. Aebi S., and Pagani O. Treatment of premenopausal women with early breast cancer: old challenges and new opportunities. Drugs 67 (2007) 1393-1401
25. Cella D., Fallowfield L., Barker P., Cuzick J., Locker G., and Howell A. Quality of life of postmenopausal women in the ATAC ("Arimidex", Tamoxifen, alone or in combination) trial after completion of 5 years'adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100 3 (2006) 273-284
26. Fallowfield L.J., Bliss J.M., Porter L.S., Price M.H., Snowdon C.F., Jones S.E., et al. Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24 (2006) 910-917
27. Whelan T.J., Goss P.E., Ingle J.N., et al., Assessment of quality of life in MA 17: a randomized placebo controlled trial of letrozole after 5 years of tamoxifen in post-menopausal women. J Clin Oncol 23 (2005) 6931-6940
28. Karnon J, Delea T, Barghout V. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective. Eur J Health Econ 2007, in press.